J
Jean-François Tanguay
Researcher at Montreal Heart Institute
Publications - 204
Citations - 8323
Jean-François Tanguay is an academic researcher from Montreal Heart Institute. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 42, co-authored 185 publications receiving 7560 citations. Previous affiliations of Jean-François Tanguay include Université de Montréal.
Papers
More filters
Journal ArticleDOI
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J. Price,Peter B. Berger,Paul S. Teirstein,Jean-François Tanguay,Dominick J. Angiolillo,Douglas Spriggs,Sanjeev Puri,Mark Robbins,Kirk N. Garratt,Olivier F. Bertrand,Michael E. Stillabower,Joseph Aragon,David E. Kandzari,Curtiss T. Stinis,Michael S. Lee,Steven V. Manoukian,Christopher P. Cannon,Nicholas J. Schork,Eric J. Topol +18 more
TL;DR: In this paper, the authors evaluated the effect of high-dose compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity after percutaneous coronary intervention (PCI), but a treatment strategy for this issue was not well defined.
Journal ArticleDOI
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Shamir R. Mehta,Jean-François Tanguay,John W. Eikelboom,Sanjit S. Jolly,Campbell D. Joyner,Christopher B. Granger,David P. Faxon,Hans-Jürgen Rupprecht,Andrzej Budaj,Alvaro Avezum,Petr Widimsky,Philippe Gabriel Steg,Jean-Pierre Bassand,Gilles Montalescot,Carlos Macaya,Giuseppe Di Pasquale,Kari Niemelä,Andrew E. Ajani,Harvey D. White,Susan Chrolavicius,Peggy Gao,Keith A.A. Fox,Salim Yusuf +22 more
TL;DR: In patients undergoing PCI for acute coronary syndromes, a 7-day double-dose clopidogrel regimen was associated with a reduction in cardiovascular events and stent thrombosis compared with the standard dose.
Journal ArticleDOI
Lower incidence of thrombus formation with cryoenergy versus radiofrequency catheter ablation.
Paul Khairy,Patrick Chauvet,John W. Lehmann,Jean Lambert,Laurent Macle,Jean-François Tanguay,Martin G. Sirois,Domenic Santoianni,Marc Dubuc +8 more
TL;DR: RF energy is significantly more thrombogenic than cryoenergy, with a higher incidence of thrombus formation and largerThrombus volumes, likely reflecting intact tissue ultrastructure with endothelial cell preservation.
Journal ArticleDOI
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Matthew J. Price,Dominick J. Angiolillo,Paul S. Teirstein,Elizabeth O. Lillie,Steven V. Manoukian,Peter B. Berger,Jean-François Tanguay,Christopher P. Cannon,Eric J. Topol +8 more
TL;DR: In the GRAVITAS trial, achievement of on-clopidogrel reactivity <208 P2Y12 reaction units at 12 to 24 hours after percutaneous coronary intervention or during follow-up was associated with a lower risk for cardiovascular events.
Journal ArticleDOI
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure
Yoshiaki Kawase,Hung Q. Ly,Hung Q. Ly,Fabrice Prunier,Djamel Lebeche,Yanfen Shi,Hongwei Jin,Lahouaria Hadri,Ryuichi Yoneyama,Kozo Hoshino,Yoshiaki Takewa,Susumu Sakata,Richard Peluso,Krisztina Zsebo,Judith K. Gwathmey,Jean-Claude Tardif,Jean-François Tanguay,Roger J. Hajjar +17 more
TL;DR: It is reported that long-term overexpression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function, potentially prevented diastolic dysfunction, and improved ventricular remodeling in a swine heart failure model.